The main treatment modality for coronary artery myocardial bridges is pharmacological, which includes controlling blood pressure, slowing down the heart rate, and reducing myocardial contractility. Coronary stenting is very prone to coronary artery rupture due to dysplasia of the middle layer of the coronary artery in the myocardial bridge portion. There are two possible approaches to surgery, one is coronary artery bridging, which from the available national and international reports does not work well and most patients will have coronary artery bridge occlusion due to the presence of competing coronary artery blood flow. Myocardial bridge dissection has the potential to lead to the development of pseudoventricular wall tumors, which is a very dangerous complication. The vast majority of patients will have significant results after 3-6 months of regular drug therapy. The incidence of this anatomical variant is not low, but not many people develop symptoms, and even fewer people have surgery or intervention. Many physicians in China have little experience with this disease and do not carefully review the literature and recommend that patients have surgery or stent placement, a problematic decision-making process. Treatment of coronary artery myocardial bridges is primarily pharmacological, including beta-blockers and calcium channel blockers, also known as betalactam and diltiazem.